Aarti Drugs Ltd.

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2010

(Rs. In Lacs except for share data)

PARTICULARS			For the Quarter Ended	For the Quarter Ended	For the Year ended	For the Year ended	Consolidated For theYear ended
PARTICULARS			31st Mar 2010	31st Mar 2009	31st Mar 2010	31st Mar 2009	31st Mar 2010	31st Mar 2009
1.	(a)	(Net) Sales / Income from operations	12,692	10,680	47,142	37,650	47,850	38,212
	(b)	Other Operating Income	-	-	-	-	-	-
2.	Expenditure
	(a).	(Increase) / Decrease in stock in trade	400	1,212	376	695	316	889
	(b).	Consumption of raw materials.	5,932	4,651	23,179	21,077	23,177	21,388
	(c).	Purchase of Traded Goods	2,258	1,311	8,202	3,443	7,732	2,522
	(d).	Employees cost	351	336	1,362	1,114	1,477	1,200
	(e).	Depreciation	348	319	1,352	1,104	1,703	1,448
	(f).	Other expenditure	1,902	1,534	6,859	5,648	7,108	5,779
	(g).	Total Expenditure	11,191	9,363	41,330	33,081	41,513	33,225
3.	Profit from Operating before Other Income		1,501	1,317	5,811	4,570	6,337	4,987
4.	Other Income		11	1	45	17	63	52
5.	Profit before Interest & Exceptional Items		1,512	1,318	5,856	4,587	6,400	5,040
6.	Interest		331	508	1,474	2,272	1,660	2,435
7.	Profit after Interest but before Exceptional Items		1,181	810	4,382	2,315	4,740	2,604
8.	Exceptional Items		-	-	-	-	-	-
9.	Profit from Ordinary Activities before Tax		1,181	810	4,382	2,315	4,740	2,604
10.	Tax Expenses (Includes)		458	354	1,772	810	1,896	847
		Provision for Taxation	391	272	1,502	540	1,642	580
		Provision for FBT	-	4	-	15	-	16
		Provision for Deffered Taxation	68	78	270	255	254	251
11.	Net profit from ordinary Activities after Tax		723	456	2,610	1,505	2,844	1,757
12.	Extraodinary Item (net of tax expenses )
13.	Net Profit for the period		723	456	2,610	1,505	2,844	1,757
	Less :
	( a)	Minority Interest	-	-	-	-	38	86
	( b)	Adjustments on Consolidation	-	-	-	-	3	19
	( c)	Share of Loss in Associate	-	-	-	-	(19)	56
	Profit After Consolidation adjustments		723	456	2,610	1,505	2,823	1,597
14.	Paid-up Equity Share Capital of Rs.10/- each.		1,211	1,171	1,211	1,171	1,211	1,171
15.	Reserves & Surplus (excluding revaluation reserves)		-	-	12,898	10,827	13,434	11,153
16.	Basic E P S (in Rs.)		5.97	3.90	22.08	12.85	23.88	13.64
17.	Public Shareholding
		Number of Shares	6051226	5495949	6051226	5495949	6051226	5495949
		Percentage of Total Shareholding	49.97	46.94	49.97	46.94	49.97	46.94
18.	Promoters & Promoter Group Shareholding**
	a)	Pledged/Encumbered
		- Number of Shares	NIL	NIL	NIL	NIL	NIL	NIL
		-Percentage of shares( as a percentage of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
		-Percentage of shares( as a percentage of total sharecapital of the Company)	NIL	NIL	NIL	NIL	NIL	NIL
	b)	Non-encumbered
		- Number of Shares	6057324	6212601	6057324	6212601	6057324	6212601
		-Percentage of shares( as a percentage of total shareholding of promoter and promoter group)	100	100	100	100	100	100
		-Percentage of shares (as a percentage of total sharecapital of the Company)	50.03	53.06	50.03	53.06	50.03	53.06

Notes :

The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 26th May 2010.

The Board of Directors has recommended Dividend of Rs.5/-per share (50%) on 1,21,08,550 Equity shares of Rs.10/- each fully paid-up for the Financial year 2009-10

Company is operating as a Single Segment Company, engaged in pharmaceuticals business hence, the disclosure requirement as per AS - 17 'Segment Reporting' is not attracted.

Figures of the previous periods have been regrouped and rearranged wherever necessary.

Timing of the accrual and accounting of Directors' Commission has been changed. This has been done to facilitate better presentation of accounts. Due to this , net profit for the year and the reserves are lower and the current liabilities & provisions are higher by Rs.92.44 lacs.

Number of Investors complaints (i) pending at the begaining of quarter 1 (ii) received during the quarter : 7 (Iii) redressed : 7 (iv) pending at the end of the quarter : 1.

For and on behalf of the Board

FOR AARTI DRUGS LIMITED